Press Release

Press release DCAT

FOR IMMEDIATE RELEASE

 

FLAMMA Opens New cGMP Kilo Lab Suite in Italy and plans construction of new R&D building

 

Chignolo D’Isola, Bergamo, Italy – MARCH 20, 2019 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that it has completed the construction of its first cGMP Kilo Lab at its Chignolo D’Isola Headquarters in Italy.

 

The cGMP Kilo Lab is currently being used for an internal Flamma project in conjunction with its Flow Chemistry Pilot Unit. Meanwhile, customers with projects are reserving production slots for later in 2019.

 

This investment is part of the Flamma 2020 Plan to bring improvement across its network of manufacturing sites. This addition to the Chignolo site adds another option when working with Flamma’s API site.

 

GianMarco Negrisoli, Corporate Development Manager at Flamma and CEO of Flamma Innovation, remarked: “The opening of a cGMP kilo lab not only increases capabilities of our facility but also allows our customers greater flexibility in working with Flamma. The ability to place projects in Italy or China and knowing that Flamma is actively managing all our sites is comforting to our customer base.”

 

Flamma will also begin construction of its new R&D building at our headquarters in Chignolo later this year. “This will quadruple our R&D space thus allowing to continue to grow our staff of researchers to serve the pharma industry and the demands of our current customers as well as future customers,” noted Kenneth Drew, Ph.D., Sr. Director North America Sales and Business Development. “The additional benefit of this addition is the ability to have a fully dedicated analytical building for our growing quality team.”

 

“Flamma continues to differentiate ourselves from others with our transparency and long-term vision with customers. We are proud to be family owned and run since 1950 since we do not have to answer to demands made from shareholders, private equity groups, or venture capital firms” notes Drew.

 

To learn more about Flamma, they will be present at numerous upcoming 2019 industry events to discuss its plans. These events include DCAT in New York City in March 2019, CPhI North America in Chicago in April/May 2019 as well as CPhI Worldwide in Frankfurt in November 2019.

 

 

 

Contact: Kenneth Drew, Ph.D.,

 

Sr. Director, North America Sales and Business Development

 

Tel: 1-617-515-0975

 

Email: ken.drew@flammagroup.com

 

 

About Flamma:

FLAMMA is a family owned & run, fully integrated CMO based in Bergamo (near Milan in Northern Italy) established in 1950.

 

FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.

 

FLAMMA has three manufacturing facilities all with R&D labs. Both cGMP Italian locations (Chignolo & Isso) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, has a new R&D building as well as a cGMP production plant. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer’s compound on-time and with the desired specifications. Flamma offers cost-effective services to customers looking for a trusted partner within China.

 

Being a fully integrated company allows Flamma to move your compounds quickly along their journey taking into consideration all aspects necessary for the success of your project.

 

Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 450 m3 and over 550 employees, see why Flamma should be your next contract manufacturer. FLAMMA- WHERE IT MATTERS MOST.

 

For more information, please visit www.flammagroup.com

 

https://www.linkedin.com/company/flamma-spa/

 

https://twitter.com/flammagroup

 

https://www.facebook.com/TheFlammaGroup/

powered by Yourbiz